Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms.
Ferencz B, Török K, Pipek O, Fillinger J, Csende K, Lantos A, Černeková R, Mitták M, Škarda J, Delongová P, Megyesfalvi E, Schelch K, Lang C, Solta A, Boettiger K, Brcic L, Lindenmann J, Rényi-Vámos F, Aigner C, Berta J, Megyesfalvi Z, Döme B.
Cancer Immunol Immunother. 2024 May 2;73(6):114. doi: 10.1007/s00262-024-03704-7.
PMID:38693435
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma.
Xiao G, Li L, Tanzhu G, Liu Z, Gao X, Wan X, Xiao D, Chen L, Xia X, Zhou R.
Inflammatory myofibroblastic tumor of the lung in children: anaplastic lymphoma kinase (ALK) expression and clinico-pathological correlation.
Siminovich M, Galluzzo L, López J, Lubieniecki F, de Dávila MT.
Pediatr Dev Pathol. 2012 May-Jun;15(3):179-86. doi: 10.2350/11-10-1105-OA.1. Epub 2012 Jan 26.
PMID:22280150
Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast.
Mituś JW, Blecharz P, Walasek T, Reinfuss M, Jakubowicz J, Kulpa J.
World J Surg. 2016 Feb;40(2):323-8. doi: 10.1007/s00268-015-3262-7.
PMID:26464157
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.
Bahce I, Dickhoff C, Schneiders FL, Veltman J, Heineman DJ, Hashemi SMS, Vrijmoet A, Houda I, Ulas EB, Bakker J, van de Ven P, Bouwhuis N, Meijboom LJ, Oprea-Lager DE, van Maldegem F, Fransen MF, de Gruijl TD, Radonic T, Senan S.